home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Target For Parkinson's Disease

  February, 7 2007 9:18
your information resource in human molecular genetics
Results from a mouse study have highlighted a possible new target for treating Parkinson's disease. Therapies that boost the brain's own levels of cannabinoids may work well alongside those that boost dopamine levels, suggests a paper in the 08 Feb 07 issue of Nature (Vol. 445, No. 7128, pp. 643-647).

Anatol C. Kreitzer and Robert C. Malenka gave mice displaying Parkinson's-disease-like symptoms two drugs. The first reduces the breakdown of naturally occurring brain cannabinoids; the second boosts activity at a specific type of dopamine receptor. After treatment, the animals' motor symptoms improved.

Critically, the team provides a potential mechanism for their finding. Together, the two drugs restore a specific type of cellular plasticity, known as long-term depression, where synaptic strength becomes weakened. The effect occurs in a subset of cells that resides in one of the major neural pathways controlling movement, and which is thought to be impaired in Parkinson's disease.


Robert C. Malenka (Stanford University Medical Center, Palo Alto, CA, USA)
E-mail: malenka@stanford.edu

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.